Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Priority 1 the USPTO review & Improved Communication
4
May 07, 2008 07:18PM
5
May 07, 2008 08:00PM
1
May 08, 2008 04:27AM
3
May 08, 2008 07:49AM

SGE,

I agree with you, our focus now should be on the patent validation by the USPTO. IMO this is the thorn in the side of TPL during licensing negotiations at this time. I also believe there are contingencies to the validation of the patents.

If the patents are revalidated we should expect good things to come. If they are not revalidated game over.

A close second focus should be on continuing to pressure PTSC for better communication to shareholders and potential investors. A suggestion may be to take one of the latest PR's and have one of our best novel writers (SGE) spice it up a little and fire it back to PTSC as an example of how they could improve selling the MMP to the investment world.

Another idea for improving communication is to come up with a list of general questions that shareholders would like addressed. A non answer should result in PTSC telling us why the question can't be answered. No double talk or lawyer answers, but plain talk that investors with a broad background can understand. General questions with a broad application that don't ask for specifics or details of individual licenses to conform to NDA's. IMO RG's letters should focus on this to improve shareholder trust and confidence as well as address concerns of potential investors. As a result IMO the SP will reverse this slide we have been on for a year.

All the best,

Steve

Share
New Message
Please login to post a reply